[161Tb]Tb-PSMA-I&T
/ Peter MacCallum Cancer Centre
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
July 06, 2025
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.
(PubMed, Lancet Oncol)
- P1/2 | "[161Tb]Tb-PSMA-I&T is safe at the maximum administered dose of 7·4 GBq. Further investigation of this promising radionuclide is warranted in larger, randomised clinical trials."
Journal • P1/2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Pain • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor
May 10, 2025
First-in-human results of Terbium-161 [161Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase I/II study
(SNMMI 2025)
- P1/2 | "Purpose/Background: Terbium-161 (161Tb) is a novel radionuclide emitting beta-radiation similar to lutetium-177 (177Lu), and also higher-energy, ultra-short path-length Auger and conversion electrons. Between October 14, 2022 and February 15, 2024, 30 eligible patients were enrolled. Median (IQR) age 69.0 years (66.0-74.8), median baseline PSA 26.9 ng/mL (10.1-70.0), median PSMA SUVmean 8.2 (7.4-10.8) and 20 patients (67%) had received prior docetaxel. There were no dose-limiting toxicities."
Clinical • Metastases • P1/2 data • Anemia • Castration-Resistant Prostate Cancer • Fatigue • Genito-urinary Cancer • Hematological Disorders • Oncology • Pain • Prostate Cancer • Solid Tumor • Xerostomia
April 23, 2025
First-in-human results of terbium-161[161Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.
(ASCO 2025)
- P1/2 | "Median (IQR) age 69.0 years (66.0-74.8), median baseline PSA 26.9 ng/mL (10.1-70.0), PSMA SUVmean 8.2 (7.4-10.8) and 20 patients (67%) had received prior docetaxel. [161Tb]Tb-PSMA-I&T displayed highly encouraging efficacy with few Grade 3 or 4 adverse events. An additional cohort to assess a higher administered radioactivity is planned. Main treatment-related adverse events."
Clinical • Metastases • P1/2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Pain • Prostate Cancer • Solid Tumor
April 07, 2025
VIOLET: EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T
(clinicaltrials.gov)
- P1/2 | N=42 | Recruiting | Sponsor: Peter MacCallum Cancer Centre, Australia | Active, not recruiting ➔ Recruiting | N=30 ➔ 42 | Trial primary completion date: Aug 2024 ➔ Aug 2025
Enrollment change • Enrollment open • Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • AR
October 19, 2024
Radiation absorbed dose in patients with metastatic castration-resistant prostate cancer treated with [161 Tb]Tb-PSMA-I&T
(PCF 2024)
- P1/2 | "Conclusion Beta radiation absorbed dose following [161Tb]Tb-PSMA-I&T are within a safe and expected range for normal organs. Additional radiation from Auger electrons is not accounted for in current models."
Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
July 12, 2024
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T.
(PubMed, J Nucl Med)
- " Enrollment was completed in February 2024. Patients are still receiving [161Tb]Tb-PSMA-I&T."
Journal • Metastases • P1/2 data • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Pain • Prostate Cancer • Solid Tumor
May 08, 2024
Radiation absorbed dose in patients with metastatic castration-resistant prostate cancer treated with [161Tb]Tb-PSMA-I&T
(SNMMI 2024)
- P1/2 | "Beta radiation absorbed dose following [161Tb]Tb-PSMA-I&T are within a safe and expected range for normal organs. Additional radiation from Auger electrons is not accounted for in current models."
Clinical • Metastases • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor
March 18, 2024
VIOLET: EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T
(clinicaltrials.gov)
- P1/2 | N=30 | Active, not recruiting | Sponsor: Peter MacCallum Cancer Centre, Australia | Recruiting ➔ Active, not recruiting
Enrollment closed • Metastases • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • AR
1 to 8
Of
8
Go to page
1